Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
HETEROARYL DERIVATIVE PARP INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/051716
Kind Code:
A1
Abstract:
Provided are a compound represented by formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate and eutectic or deuterated material thereof, or a pharmaceutical composition comprising same, and a use thereof as a PARP-1 inhibitor in the preparation of a drug for treating related diseases.

Inventors:
LI YAO (CN)
WANG WENJING (CN)
CHEN LEI (CN)
KANG PENG (CN)
FU CHAO (CN)
HE TIANCHENG (CN)
FANG LINYONG (CN)
GUI NAICHENG (CN)
TANG PINGMING (CN)
YU YAN (CN)
ZHANG CHEN (CN)
YAN PANGKE (CN)
Application Number:
PCT/CN2022/122710
Publication Date:
April 06, 2023
Filing Date:
September 29, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
HAISCO PHARMACEUTICAL GROUP CO LTD (CN)
International Classes:
C07D471/04; A61K31/496; A61K31/498; A61K31/501; A61P35/00; A61P35/02; C07D265/36; C07D401/12; C07D498/04
Domestic Patent References:
WO2021260092A12021-12-30
WO2022074617A12022-04-14
WO2021013735A12021-01-28
WO2010111626A22010-09-30
WO2009053373A12009-04-30
Foreign References:
CN102341394A2012-02-01
Other References:
JOHANNES, J. W. ET AL.: "Discovery of 5-{4-[(7-Ethyl-6-oxo-5, 6-dihydro-1, 5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide(AZD5305):A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 19, 27 September 2021 (2021-09-27), pages 14498 - 14512, XP093028792, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.1c01012
Attorney, Agent or Firm:
BEIJING SANYOU INTELLECTUAL PROPERTY AGENCY LTD. (CN)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: DATA PROCESSING METHOD AND APPARATUS, PROCESSOR, AND HYBRID MEMORY SYSTEM

Next Patent: FUSED RING COMPOUND ACTING AS SHP2 INHIBITOR